BioNTech (BNTX) Chief Medical Officer details option and PSU holdings in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioNTech SE’s Chief Medical Officer, Ozlem Tureci, filed an initial Form 3 disclosing existing equity-based awards, rather than new share purchases or sales. The filing lists option grants over 18,416, 25,459 and 9,306 underlying ordinary shares, phantom options over 7,112 and 14,664 shares, and 11,633 performance share units.
Footnotes explain that these options and PSUs generally vest in equal annual installments over four years and become exercisable four years after grant, subject to performance-based conditions tied to BioNTech’s share price and, for PSUs, its performance relative to the Nasdaq Biotechnology Index.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Tureci Ozlem
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Phantom Option | -- | -- | -- |
| holding | Phantom Option | -- | -- | -- |
| holding | Performance Share Unit | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 18,416 shares (Direct);
Phantom Option — 7,112 shares (Direct);
Performance Share Unit — 11,633 shares (Direct)
Footnotes (1)
- The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price. The exercise price of this option is EUR 75.91. The exercise price of this option is EUR 93.35. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
FAQ
What does BioNTech (BNTX) Chief Medical Officer report on this Form 3?
The filing reports existing equity awards held by BioNTech’s Chief Medical Officer, not new trades. It lists options, phantom options, and performance share units linked to ordinary shares, outlining the size of each award and their exercise and expiration dates.
What types of equity awards does Ozlem Tureci hold in BioNTech (BNTX)?
She holds options to buy ordinary shares, phantom options, and performance share units. Each award references underlying ordinary shares, with specific exercise prices and long-dated expiration dates, reflecting a mix of share-settled and cash-settled incentive instruments.
How do the phantom options for BioNTech (BNTX) Chief Medical Officer work?
Each phantom option entitles the holder to a cash payment equal to the difference between an exercise closing price and the exercise price. The exercise closing price is defined as the average ADS closing price over the ten trading days before exercise.
Can BioNTech (BNTX) equity awards be settled in ADSs or cash?
Yes. Options may be settled in ordinary shares, American Depositary Shares, and/or cash at the supervisory board’s election. Performance share units can similarly be settled in one ordinary share, one ADS, cash, or another form equal to the economic share value.